<DOC>
	<DOCNO>NCT00358644</DOCNO>
	<brief_summary>The purpose study estimate rate complete remission , well overall survival , old patient Acute Myeloid Leukemia ( AML ) .</brief_summary>
	<brief_title>Study Decitabine Treatment Older Patients With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . A diagnosis AML transform myelodysplastic syndrome ( MDS ) within 2 week study enrollment . 2 . Ineligible receive intensive chemotherapy disease . 3 . Have receive chemotherapy within 4 week study enrollment must recover treatmentrelated toxicity . 1 . Received previous treatment AML . 2 . Previously receive Vidaza . 3 . Received investigational agent within 30 day first dose study drug . 4 . Uncontrolled intercurrent illness . 5 . Had radiotherapy within 14 day prior study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Dacogen</keyword>
	<keyword>MGI PHARMA , INC .</keyword>
</DOC>